{
  "documents": [
    "Core Curriculum Hypertension in chronic kidney disease: Core Curriculum 2019 Elaine Ku, Benjamin J. Lee, Jenny Wei, and Matthew R. Weir Hypertensionandchronickidneydisease(chronic kidney disease)arecloselyinterlinkedpathophysiologicstates, such Completeauthorandarticle thatsustainedhypertensioncanleadtoworseningkidneyfunctionandprogressivedeclineinkidney informationprovidedatthe function can conversely lead to worsening Blood Hypertension (blood pressure) control. The pathophysiology of hyendofthearticle. pertensioninCKDiscomplex andis asequelaofmultiplefactors, includingreducednephronmass, AmJKidneyDis. 74(1): increased Sodium retention and extracellular volume expansion, sympathetic nervous system over120-131. Publishedonline activity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial March19, 2019. dysfunction. Currently, thetreatmenttargetforpatientswithCKDisaclinicsystolicBP130mmHg. doi: 10. 1053/ The main approaches to the management of hypertension in chronic kidney disease include dietary salt restriction, j. ajkd. 2018. 12. 044 initiationoftreatmentwithangiotensin-convertingenzymeinhibitorsorangiotensinreceptorblockers, 2019bytheNational and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and KidneyFoundation, Inc. mortalityandaccelerateprogressiontoend-stagekidneydisease. AlthoughintensiveBPcontrolhas notbeenshowninclinicaltrialstoslowtheprogressionofCKD, intensiveBPcontrolreducestherisk foradversecardiovascular outcomes andmortality inthe CKDpopulation. Introduction Several putative mechanisms contribute to FEATURE EDITOR: elevated blood pressure in patients with chronic kidney disease, including Hypertensioniscommoninpatientswithchronic AsgharRastegar neural andhormonal changesthat oftenactin Kidney disease (chronic kidney disease). The prevalence ranges from 60% to 90% depending on the stage of concert to disrupt appropriate blood pressure regulation ADVISORYBOARD: (Fig 1). UrsulaC. Brewster chronic kidney disease and its cause. The mechanisms of hyperchronic kidney disease is associated with increased activity MichaelChoi tension in chronic kidney disease include volume overload, symof the RAAS. There is reduced Blood flow in AnnOHare pathetic overactivity, salt retention, endothelial ManoocherSoleimani peritubular capillaries downstream of scledysfunction, andalterationsinhormonalsystems rosed glomeruli. As a result of this reduced thatregulatebloodpressure(blood pressure). Hypertension TheCoreCurriculum effective (perceived) Blood flow, glomeruli remains a leading attributed cause of end-stage aimstogivetrainees in these regions hypersecrete renin, thereby innephrologya kidneydisease(end-stage kidney disease)intheUnitedStates. Unincreasing circulating angiotensin II levels. strongknowledge controlled hypertension is also associated with Angiotensin II has a direct vasoconstrictor baseincoretopicsin higherriskforcardiovascular(CV)morbidityand thespecialtyby effect, which increases systemic vascular mortality. InthisCoreCurriculum, wereviewthe providinganoverresistance and blood pressure. Because there are fewer pathophysiology, diagnosis, and management viewofthetopicand functioning glomeruli in chronic kidney disease, each citingkeyreferences, ofhypertensioninpatientswithCKD. remaining glomerulus must increase its includingthefoundaglomerular estimated glomerular filtration rate (glomerular filtration rate): increasing tionalliteraturethat ledtocurrentclinical Pathophysiology of Hypertension in systemic arterial Hypertension helps bolster approaches. chronic kidney disease perfusion Hypertension and glomerular filtration rate. Angiotensin II also promotes Sodium reabQuestion 1: All of the following mechanisms sorption in the proximal tubule and (through have been implicated in the development of aldosterone)thecollectingduct. Moreover, net hypertension in patients with chronic kidney disease except loss of overall glomerular filtration rate impairs Sodium excretion, (choose1): which also leads to Sodium retention. Sodium a) Sympathetic nervous system (SNS) retentioncauseshypertensionthroughvolumeoveractivity dependent and volume-independent mechab) Increasedintracellular calcium level nisms. Excess extracellular volume leads to c) Sodiumretention increasedperfusionofperipheraltissues, which d) Reversalofhypoxia-induced vasodilation stimulatesvasoconstriction, increasesperipheral e) Increased activity of the renin-angiotensinaldosterone system(RAAS) vascular resistance, and therefore increases blood pressure. f) None of the above; all these mechanisms Extracellularvolumeexpansionalsoleadstothe havebeen implicated productionofouabain-likesteroidsthatinduce vasoconstriction and therefore increase periphFor the answer to this question, see the eral vascular resistance. Volume-independent following text. mechanismsincludeincreasedvascularstiffness 120 AJKD Vol74Iss1July2019 Core Curriculum Reduced glomerular mass Endothelial dysfunction Increased renin Decreased sodium production excretion Increased Sympathetic angiotensin II nervous system overactivity Increased sodium resorption sodiumretention Increased peripheral Extracellular Increased vasoconstriction volume arterial stiffness expansion Increased systemic Blood Hypertension Figure1. Pathophysiologic mechanismsofhypertension inchronickidneydisease. andincreasedcentralsympatheticoutflow(adirectsequelaof andsodiumchloridedeliverytothemaculadensa(tubuloincreasedextracellularsodium). glomerular feedback) are part of the autoregulatory Overactivity of the SNS in chronic kidney disease stimulates renin proprocess that helps maintain intraglomerular Hypertension duction by the renal juxtaglomerular cells. Beyond SNS and therefore glomerular filtration rate. However, in hypertensive patients, activationbysodiumretention, renalischemiaalsoleadsto chronically elevated systemic arterial pressures cause renal afferent nerve excitation through adenosine. Finally, remodelingoftheafferentarterioleandreduceitsabilityto experimental and clinical studies suggest that angiotensin constrict and dilate.",
    "Finally, remodelingoftheafferentarterioleandreduceitsabilityto experimental and clinical studies suggest that angiotensin constrict and dilate. Over time, elevated systemic arterial IIlevels(whicharehigherinpatientswithCKDasdetailed pressures transmitted to the Kidney lead to glomerular above) directly stimulate SNS activity. hypertension, nephrosclerosis, and progressive loss of Endothelial dysfunction (including impaired nitrous kidneyfunction. oxide production), oxidative stress, and elevated endoAs the discussion shows, multiple mechanisms have thelin levels are also implicated in the pathogenesis of been implicated in the development of hypertension in hypertension in patients with chronic kidney disease. chronic kidney disease. Therefore, the correct answer to question 1 is (f). Several factors related to chronic kidney disease complications may also Additional Readings contribute to the High prevalence of hypertension among patients with chronic kidney disease. In anemic patients, treatment with Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. erythropoietin and erythropoiesis-stimulating agents can Sympathetic hyperactivity in chronic Kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004; 65: reverse hypoxia-induced vasodilation as hemoglobin 1568-1576. concentration increases. There is also evidence that these Rodriguez-Iturbe B, Romero F, Johnson RJ. Pathophysiological agents may acutely cause vasoconstriction, even before mechanisms of salt-dependent hypertension. Am J Kidney Dis. anemia is corrected. Furthermore, secondary hyperpara2007; 50: 655-672. thyroidismincreasesintracellularcalciumlevels, leadingto vasoconstriction. Because progressive chronic kidney disease is associated Defining Normal and Abnormal blood pressure in chronic kidney disease with vascular calcification, isolated systolic hypertension that is resistant to antihypertensive therapy is relatively Question2: A54-year-oldwomanwithamedicalhistoryof common. Finally, uremia may impair vasodilation by stage 3 chronic kidney disease and dyslipidemia presents to the clinic. blood pressure inhibiting nitric oxide synthase. readingstakenintriageare138/78mmHgand134/80mm While chronic kidney disease contributes to the development of hyperHg. Whichofthefollowingwould bethebest nextstep: tension, hypertensionisalsoamajorfactorintheprogresa) RepeattheBPintheclinicafter5minutes ofquiet rest sion of chronic kidney disease. Normally, the glomerular capillary loops are b) Initiate therapy with an angiotensin-converting enzyme (ACE)inhibitor shielded from elevated systemic arterial pressures by a c) Order a24-hourambulatoryBPmonitor process called autoregulation. Afferent arteriole caliber d) Tellthepatient herBPis appropriate forage changesinresponsetosystemicpressure(myogenicreflex) AJKD Vol74Iss1July2019 121 Core Curriculum higher risk for adverse CV outcomes, as well as chronic kidney disease progression. Question 3: The 24-hour ambulatory blood pressure monitoring AsubstantialproportionofpatientswithCKDhavewhite (ABPM)isconsidereda preferred metricofBPsbecause: coat (10%-20%) and masked hypertension (10%-30%), a) Clinical trials have shown that lowering ambulatory BPs reduced theriskfor CVevents which would not be detected in the absence of ABPM b) White coat hypertension is considered to be completely (Table 1). However, ABPM is not widely available and benignandshouldnever betreated reimbursementforitsperformanceispoor. Whenavailable, c) ABPM measurements are more strongly associated with elevatedBPsobtainedusinganappropriatetechniqueinthe riskforadverseoutcomes comparedwith clinicBP clinic can be confirmed with 24-hour ABPM, especially in measurements settings of suspected white coat or masked hypertension. d) Home blood pressure measurements are usually not performed ABPM can also be useful for confirmation of blood pressure control correctly bypatients andarenot associated with riskfor andhelpdetecthypotensionthatmaybeoccurringoutside adverseoutcomes theofficesettinginsymptomaticpatients. For theanswerstothesequestions, seethefollowing text. Home blood pressure Monitoring Out-of-officeBPmeasurements(eg, homeBPmonitoring) are more practical than ABPM and can be a useful tool for Accurate blood pressure measurement is critical to the diagnosis monitoring BPs during therapy. Automated devices that and management of chronic kidney disease. Most clinical blood pressure measurements havebeenvalidatedshouldbeused, andindividualsshould are obtained in the office and these measurements are betrainedtomeasureBPintheappropriatefashion(asfor commonly used during treatment decisions, although officeBPmeasurements). Tworeadingsshouldbetakenat 24-hour ABPM is preferred for the confirmation of each sitting, twice a day. Although the evidence is less abnormal BPs. Office blood pressure measurements should be obrobust than 24-hour ABPM, home blood pressure measurements have tained in standardized fashion after 5 minutes of quiet also been associated with risk for adverse outcomes in a rest using a validated device that is routinely calibrated.",
    "similar fashion as ABPM and can be a useful adjunct for The cuff should be placed on the arm at the level of the improving blood pressure control, especially if combined with teleatrium with the correct cuff size (the bladder of the cuff health counseling. should encircle 80% of the arm), and the patient should besittingwithfeetflatonthegroundandbacksupported blood pressure Classification and Correlations Between BPs by a chair. At least 2 readings should be obtained in Taken in Different Settings the office. Caffeine and exercise should be avoided 30 Based on the most recent American Heart Association/ minutes before blood pressure measurement. blood pressure measurement errors American College of Cardiology (AHA/ACC) guidelines, are common in routine clinical practice, so accurate assessment of blood pressure is critical during the diagnosis and monitoring of hypertension. All major adult clinical Table1. DefinitionsofNormalandAbnormalBPBasedonthe trial data related to the effect of blood pressure treatment on 2017AHA/ACC Guideline inPatientsWithCKD renal and CV outcomes have used BPs obtained in the Daytime clinic setting under standardized protocols with serial blood pressure Classificationa OfficeBP ABPMorHomeBP measurements. Normalorelevated 130/80mm 130/80mmHg blood pressure Hg Sustained hypertension ≥130/80mm ≥130/80mmHg Ambulatory blood pressure Monitoring Hg Because of the stronger association between BPs obtained Whitecoathypertension ≥130/80mm 130/80mmHg from ABPM with CV and renal outcomes, 24-hour ABPM Hg has been considered the preferred metric of blood pressure in both Maskedhypertension 130/80mm ≥130/80mmHg Hg the general population and patients with chronic kidney disease. During 24-hour ABPM, an appropriate-size blood pressure cuff is worn for Difficult-to-Control 24 hours, with measurements taken every 15 to 20 myocardial infarctionblood pressure Definition nutes during the daytime and every 30 to 60 minutes Resistant Receiving≥3antihypertensive agents, during sleep. Thus, an advantage of ABPM is the provihypertension 1ofwhichis adiuretic, without sion of readings during sleep that allows for assessment adequateBPcontrol of appropriate nocturnal physiologic dipping (blood pressure should Refractory Receiving≥3antihypertensive agents, decrease by 10% during sleep) and blood pressure variability. The hypertension 1ofwhichis athiazide-typediuretic andanotherofwhichisspironolactone, presence of masked hypertension (defined as normal without adequateBPcontrol office BPs but elevated out-of-office BPs) has been Abbreviations: ABPM, ambulatory Blood Hypertension monitoring; AHA/ACC, associated with higher risk for CV disease in patients AmericanHeartAssociation/AmericanCollegeofCardiology; blood pressure, bloodpressure; chronic kidney disease, chronickidneydisease. with and without chronic kidney disease. Both nocturnal hypertension aAsrecommendedby2017ACC/AHAguideline(Wheltonetal. JAmCollCardiol. and nondipping status have also been associated with 2018; 71(19): 2199-2269). 122 AJKD Vol74Iss1July2019 Core Curriculum an office blood pressure 120/80mm Hg is considered to be Additional Readings normal, and office BPs in the range of 120to 130/ Agarwal R, Andersen MJ. Prognostic importance of ambulatory 80mmHgareconsideredtobeelevated. AnofficeBP≥ bloodpressurerecordingsinpatientswithchronickidneydisease. 130/80mm Hg would meet the threshold for hyperKidneyInt. 2006; 69: 1175-1180. tension. Although the Systolic blood pressure Intervention Trial Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory Blood-Hypertension measurements and (SPRINT) found that assignment to a systolic blood pressure treatment goal 120mm Hg lowered the risk for CV events mortality. N Engl J Med. 2018; 378: 1509-1520. ESSENTIAL READING and death, given that the BPs measured in routine clinic PickeringTG, HallJE, AppelLJ, etal. Recommendationsforblood visits are unlikely to be obtained in the same standardpressuremeasurementinhumansandexperimentalanimals: part ized approach as in trials such as SPRINT (eg, unob1: bloodpressuremeasurementinhumans: astatementforproserved using an automated device), routine clinic BPs fessionals from the Subcommittee of Professional and Public could be 5 to 10mm Hg higher than BPs obtained in Education of the American Heart Association Council on High Blood Hypertension Research. Circulation. 2005; 111: 697-716. clinical trials such as SPRINT. Thus, treatment to a systolic blood pressure target 120mm Hg based on BPs obtained in ESSENTIALREADING Whelton PK, Carey RM, Aronow WS, et al.",
    "2017 ACC/ routine clinical practice could potentially lead to overAHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA treatment of blood pressure. guideline for the prevention, detection, evaluation, and manAn office blood pressure of 140/90mm Hg is thought to correlate agement ofhigh bloodpressure in adults: executive summary: with an ABPM 24-hour average blood pressure of 130/80mm Hg a report of the American College of Cardiology/American (135/85mm Hg daytime and 120/70mm Hg nighttime Heart Association Task Force on Clinical Practice Guidelines. J Am Soc Hypertens. 2018; 12: 579 e571-579 e573. mean BPs) and a mean home blood pressure of 135/85mm Hg. The ESSENTIALREADING appropriate classification of BPs using a combination of office and ambulatory BPs (when available) are shown in Hypertension Workup and Differential Diagnosis in Table 1. chronic kidney disease Resistant and refractory hypertension (Table 1) in chronic kidney disease are common, especially in chronic kidney disease stages 4 to 5, Question 4: A 42-year-old woman with stage 3 chronic kidney disease and for which multiple classes of complementary antihyperpreviously well-controlled hypertension for 10 years has tensive agents are frequently needed to achieve blood pressure required escalation of antihypertensive therapy from 1 to 4 control. medicationsinthelastfewmonths. Sheisasymptomatic. She Because the majority of clinical trials in patients with doesnothaveafamilyhistoryofhypertension. BPmeasured and without chronic kidney disease have targeted office-measured BPs, in the clinic is 160/90mm Hg in both arms and legs. On laboratory evaluation, she has metabolic alkalosis but has most guidelines (including Kidney Disease: Improving Global Outcomes) continue to recomneverbeenhypokalemic. Kidneysizesonrenalultrasoundare mend treatment of hypertension based on officenormal and symmetric. What is the most appropriate next measured BPs in adults with chronic kidney disease. To date, there have step? been no large clinical trials of adults with chronic kidney disease that have a) Dopplerultrasound targeted 24-hour ABPM-derived BPs. Because of the b) Check aldosterone-to-renin ratio logistical complexity associated with routine ABPM c) Echocardiogram toevaluateforcoarctation oftheaorta performanceandlackofsolidevidencetosupportABPMd) Checkserummetanephrinelevels based BPs, we currently recommendroutine treatment of e) Reducedietarysodium intake hypertension based on office blood pressure measurements ascerQuestion5: Allofthefollowingareindicationsforworkupof tained using standardized protocols. However, in our secondaryhypertension inpatientswith CKDexcept: opinion, in the setting of resistant or refractory hypera) Onset of elevated blood pressure before puberty but after the tension, symptoms of orthostasis or hypotension among development ofCKD those receiving antihypertensive therapy and concern for b) Hypertension unresponsive to 3 antihypertensive mediautonomic dysfunction or white coat hypertension, cations, including adiuretic ABPMor home-based BPs should be obtained to help c) Acute worsening of previously well-controlled further guide treatment of hypertension in patients with hypertension chronic kidney disease. Home blood pressure monitoring may be especially useful d) Persistent hypokalemiaoffdiuretic treatment for achieving appropriate blood pressure control among patients e) Concomitantdevelopment oftremors andpalpitations f) Flash pulmonaryedema with chronic kidney disease. In the scenario raised in question 2, the patients blood pressure of Question6: TheSTAR, ASTRAL, andCORALtrialssuggest 137/78mm Hg is only mildly elevated. It is also a single that renal angioplasty with stenting may not be superior to visit reading and therefore it is best to repeat this reading medicaltherapyforrenalarterystenosis. Asaresult, workup several months later before any treatment is considered. forrenovascularhypertensionshouldbereservedforpatients Therefore, the correct answer is (a). who are more likely to improve their blood pressure with revascularization. Which of the following patient characteristics Regarding question 3, because multiple studies have suggests a higher probability of improvement in BPs after shown that ABPM more strongly correlates with adverse revascularization? outcomescomparedtoofficeBP, thecorrectansweris(c). AJKD Vol74Iss1July2019 123 Core Curriculum hypertension, increased risk of CV events, and a higher a) Resistanthypertension incidence of end-organ damage. Although hypokalemia b) Flash pulmonaryedema is more frequent in primary aldosteronism, it is detected c) Abruptonsetofhypertension d) a)andc)only in 50% of patients with primary aldosteronism.",
    "Thus, e) a), b), andc) the absence of hypokalemia should not deter providers from screening for primary aldosteronism if there are For theanswerstothesequestions, seethefollowing text. other reasons to justify this evaluation. HyperaldosteronismmayoccurasofteninpatientswithCKDas in the general population. AsbothacauseandconsequenceofCKD, hypertensionis blood pressure measurements in all 4 extremities should be highly prevalent among patients with chronic kidney disease. Additional comparedtoruleoutcoarctationoftheaorta. Patientswith workup for other causes of hypertension is warranted if episodicseverehypertension(withorwithoutheadacheor therearereasonstosuspectasecondarycauseofhypertenflushing) or a family history concerning for genetic presion(Box1). Ingeneral, furtherevaluationisrecommended disposition should have serum metanephrine levels in patients with chronic kidney disease if the onset of elevated BPs occurred checked to rule out pheochromocytoma. before puberty (and preceded the development of chronic kidney disease), Asymmetric Kidney sizes, worsening estimated glomerular filtration rate severeormalignanthypertensionthatisoutofproportionto (estimated glomerular filtration rate) with ACE inhibition or angiotensin receptor the degree of chronic kidney disease is present, sudden worsening of blood pressure blockade, presence of an abdominal bruit, or flash pulcontrol occurs in a previously hypertensive patient with monary Edema may suggest the presence of renovascular Good blood pressure control, or resistant hypertension is present hypertension. The initial screening test for renal artery (Table 1). Workup and prioritization of testing should be stenosis is Doppler ultrasonography, and peak systolic guidedbycause-specificsignsorsymptoms. velocity in the main renal artery is the best parameter for For example, patients with spontaneous or diureticthe detection of significant stenosis. To detect ≥60% induced hypokalemia should be screened for primary reduction in renal artery diameter, a peak systolic velocity aldosteronism using aldosterone-to-renin ratio. In addicutoff of 180 to 200cm/s has been proposed. tion, compared with other causes of hypertension, priThreerandomizedtrialscomparingmedicaltherapyand mary aldosteronism is characterized by more severe renal angioplasty with stenting in patients with atherosclerotic renal artery stenosis did not demonstrate differences in mortality, CV events, or progression of chronic kidney disease: the Box1. CausesofSecondary Hypertension STAR (Stent Placement in Patients With Atherosclerotic (cid: 129) Renovascular hypertension (atherosclerosis, fibromuscular Renal Artery Stenosis and Impaired Renal Function), dysplasia) ASTRAL (Angioplasty and Stenting for Renal Artery Blood- (cid: 129) Coarctation oftheaorta sions), and CORAL (Cardiovascular Outcomes With Renal (cid: 129) Primaryaldosteronism AtheroscleroticLesions)trials. Althoughselectionbiasmay (cid: 129) Pheochromocytoma have led to underestimation of the therapeutic benefits of (cid: 129) Polycystic ovary syndrome angioplasty, based on these results, only patients with a (cid: 129) Cushingsyndrome higher likelihood of improvement in BPs with revascu- (cid: 129) Hyperthyroidism, hypothyroidism (cid: 129) Obstructive sleepapnea larization should be evaluated for renovascular hypertension because angioplasty is not without risks and medical Chemical ormedication induced Caffeine, coffee managementwouldotherwisebetheprimaryapproachto Alcohol treatment. Patient factors that may increase the chances of NSAIDs improvingBPcontrolwithrevascularizationincluderecent Oralcontraceptives onset/progressionofhypertension, resistanthypertension, Steroids and flash pulmonary Edema. In addition, patients with a Calcineurin inhibitors solitary Kidney and renal artery stenosis or bilateral renal Chemotherapeutic agents (gemcitabine, VEGF receptor artery stenosis with worsening Kidney function could also inhibitors) be considered for revascularization. Illicit drugs(amphetamines, cocaine) In the vignette described in question 4, the patient has (cid: 129) Monogenicdisorders resistanthypertensionwithpoorcontroldespitetheuseof4 Liddlesyndrome antihypertensive medications. It is therefore important to Syndromeofapparentmineralocorticoid excess Glucocorticoid-remediable hypertension (familial hyperconsidersecondarycausesofhypertension. Thekeyfinding aldosteronism typeI) ispersistentmetabolicalkalosisdespiteCKD. Althoughsheis Familialhyperaldosteronism typeIII not hypokalemic, it is important to rule out primary Gordon syndrome hyperaldosteronism. Thecorrectansweristherefore(b). Subtypes ofcongenitaladrenalhyperplasia Regarding question 5, although hypertension in the Abbreviations: nonsteroidal anti-inflammatory drug, nonsteroidalanti-inflammatorydrug; VEGF, vascular pre-pubescent period is an indication for further workup, endothelialgrowthfactor. hypertension after the development of chronic kidney disease in this period 124 AJKD Vol74Iss1July2019 Core Curriculum iscommonandinitselfshouldnottriggerfurtherworkup. hypertensive patients, although a High-Potassium intake All other options require further workup. Therefore, the may be difficult to maintain without provoking hypercorrect answer is (a).",
    "Therefore, the may be difficult to maintain without provoking hypercorrect answer is (a). kalemia in patients with more advanced chronic kidney disease (eg, stage 4 Relevant to question 6, multiple studies have shown a or 5). It is unknown whether a higher Potassium diet correlationbetweenthepresenceofresistanthypertension, would lower blood pressure in patients with chronic kidney disease. Limiting alcohol abrupt onset of severe hypertension and flash pulmonary intake to no more than 2 drinks per day in men and 1 Edema, and higher likelihood of responding to revascudrinkperdayinwomencanalsohelpimproveBPcontrol. larization. Therefore, the correct answer is (e). Reducing Sodium intake also has the added benefit of reducing proteinuria. Weight loss can reduce blood pressure by w5mm Hg for every Additional Readings 5-kg weight loss, and bariatric surgery may be a potential ASTRALInvestigators; WheatleyK, IvesN, GrayR, et al. Revasoption in those deemed to be suitable candidates for this cularization versus medical therapy for renal-artery stenosis. procedure. For those with sleep apnea, treatment with N EnglJ Med. 2009; 361: 1953-1962. Cooper CJ, Murphy total protein, Cutlip DE, et al. Stenting and medical continuous positive airway Hypertension may also lead to therapy for atherosclerotic renal-artery stenosis. N Engl J Med. modestimprovementsinBP. Inaddition, bothaerobicand 2014; 370: 13-22. isometric resistance exercise can improve BPs in patients Textor SC, Lerman LO. Reality and renovascular disease: when with hypertension. Currently, 90 to 150 minutes of doesrenalarterystenosiswarrantrevascularization? AmJKidney aerobic exercise is recommended per week. Use of Dis. 2014; 63: 175-177. ESSENTIALREADING over-the-counter medications such as nonsteroidal anti-inflammatory Pain medications should be avoided Management of Hypertension because they may increase blood pressure and also adversely affect Kidney function. Question 7: Which of the following dietary or behavioral modifications has not been shown to improve blood pressure control, Renal Denervation especiallyinpatientswithCKD? Renal denervation involves radiofrequency ablation of a) A2-g/dsodium diet the network of nerves that innervate the renal artery. b) Reductioninalcohol intake The role of renal denervation for the treatment of c) Weight loss resistant (or refractory) hypertension among patients d) High-potassiumdiet with chronic kidney disease is unclear. Although the procedure itself e) Dietlowinunsaturatedfats appears to be safe, early randomized trials initially Question 8: A 60-year-old man with chronic kidney disease, Diabetes, and failed to demonstrate the superiority of renal denervahypertension is on treatment with a maximum-dose ACE tion over sham procedures among patients with resisinhibitor, but both his blood pressure and proteinuria are still not at tant hypertension and normal or mildly reduced eGFRs therapeutictargets. Whichofthefollowingwouldbethebest (45mL/min/1. 73m2) in terms of reducing office or choiceforantihypertensivetherapy, assumingthatadditional ambulatory BPs 6 months postintervention. However, proteinuriareductionisagoalandthesameBPtargetcould more recent trials have shown more promising results, beachieved withanyofthese agents? including the SPYRAL hypertension-ON MED trial, which a) Addanangiotensin receptorblocker(angiotensin receptor blocker) demonstrated that renal denervation was effective in b) Addclonidine reducing office systolic BPs by w7mm Hg compared to c) Addamlodipine a sham procedure among patients with elevated BPs d) Adddiltiazem who were receiving pharmacotherapy at baseline. A e) Addhydralazine small study of patients with chronic kidney disease also showed remarkFor theanswerstothesequestions, seethefollowing text. able reductions in blood pressure (30mm Hg) after renal denervation in more advanced chronic kidney disease (stages 3-4), and some studies have shown reductions in albuminuria and Nonpharmacologic Therapy slower progression of chronic kidney disease with renal denervation. Dietary and Behavioral Modification However, no device is currently approved in the United Nonpharmacologic therapy should be the first step to the States for routine clinical use. treatmentofhypertension, evenamongpatientswithCKD, andthemainstaysofnonpharmacologictherapyaredietary Baroreceptor Activation interventions.",
    "treatmentofhypertension, evenamongpatientswithCKD, andthemainstaysofnonpharmacologictherapyaredietary Baroreceptor Activation interventions. Dietsrichinfruitsandvegetablesandlowin Pacingofthecarotidbaroreceptorstoincreasetheiractivity saturated or unsaturated fats (such as the DASH Dietary and therefore reduce SNS activity has also been attempted Approaches to Stop Hypertension diet) can lead to as a treatment strategy for resistant hypertension. Howmoderate declines in blood pressure by w10mm Hg in hypertensive ever, thismethodhasnotbeenshowntobeefficacious. No patients. Increasing Potassium intake to 3 to 4g/d and deviceiscurrentlyapprovedintheUnitedStates, andthere reducing Sodium intake to 1. 5g/d can also lead to reare no data on the effectivenessof such devices in patients ductions in blood pressure by w5mm Hg with both interventions in with chronic kidney disease. AJKD Vol74Iss1July2019 125 Core Curriculum Pharmacologic Therapy There has been some suggestion that moving the In general, for patients with chronic kidney disease, ACE inhibitors and timing of once-daily antihypertensive therapy from ARBs are considered first-line antihypertensive agents by morning to nighttime may be beneficial for reducing CV most guidelines, especially in the presence of concurrent risk, purportedly by restoring physiologic nocturnal albuminuria (albumin excretion 300mg/d). Evidence dipping and the circadian rhythm of blood pressure variation. to support their benefit over other classes of antihyperHowever, the effect of changing only the timing of tensive agents in those without proteinuria is less robust. antihypertensive medications remains controversial in ACE inhibitors and ARBs induce efferent arteriolar terms of its long-term CV benefits. In a Cochrane Review vasodilation, which leads to reductions in intraof this issue conducted in 2011 that included mostly glomerularpressureandthereforesuppressesproteinuria. studies of patients without chronic kidney disease, bedtime dosing of This renal benefit is applicable to both patients with and antihypertensive medications was associated with better without Diabetes. However, the combination of ACE inblood pressure control, but not with a decrease in risk for adverse hibitors with ARBs has not been shown to be effective at CV or mortality outcomes. slowingthe progressionofCKDorreducingCVeventsin Table 2 provides recommendations regarding antihypatients with chronic kidney disease (with or without Diabetes). Because pertensive therapy selection among patients with chronic kidney disease. In this combination may predispose to hyperkalemia and general, ACE inhibitors and ARBs are preferred first-line acute Kidney injury, dual blockade with ACE inhibitors agents in patients with albuminuria or proteinuria, and and ARBs has generally fallen out of favor. Similarly, diuretics may be useful in combination with ACE inalthough there is some evidence to support the use of hibitorsandARBstobalancetheriskforhyperkalemiaand ACE inhibitors or ARBs with aldosterone antagonists in enhance albuminuria or proteinuria reduction. In the certain conditions such as Heart failure, patients with absence of albuminuria or proteinuria, the optimal firstchronic kidney disease receiving this regimen need to be monitored careline agent for patients with chronic kidney disease is debated and may be fully for hyperkalemia. selected based on concurrent indications, including the There is less consensus regarding the optimal secondcauseofhypertension, needtotreathyperkalemia, orfluid line class of antihypertensive agents in patients with overload. chronic kidney disease, but diuretics are a reasonable choice for most paMore recently, a new class of antihyperglycemic tients with chronic kidney disease, especially in the setting of volume medications, the SGLT2 inhibitors, has been shown to overload. Whereas loop diuretics may be preferred as be effective in reducing risk for adverse CV and glomerular filtration rate declines, especially if there is evidence of Kidney disease outcomes. They also possess antihypervolume overload, there is evidence that thiazide and tensive effects that do not appear to be related to thiazide-like diuretics are effective antihypertensive glucosuria. agents, likely through indirect vasodilatory mechanisms. Medication nonadherence is one of the major reasons Of the loop diuretics, bumetanide or torsemide may be for inadequate blood pressure control in patients with chronic kidney disease.",
    "More preferred due to its superior bioavailability. Torsemide than 50% of patients with chronic kidney disease require 3 or more also has a longer half-life than furosemide and bumetamedications to control their blood pressure, and many patients nide and can be administered once daily. Diuretics may with chronic kidney disease have a High pill burden because of belessoptimalastheantihypertensiveagentofchoicefor concurrent treatment needed for metabolic acidosis, patients with chronic kidney disease due to polycystic Kidney disease if hyperphosphatemia, and other sequelae of chronic kidney disease. It is they trigger volume depletion and vasopressin release, important to assess for nonadherence to medications as which may contribute to cyst enlargement. Nona cause of uncontrolled BPs and to simplify regimens dihydropyridine calcium channel blockers (eg, diltiazem when possible. or verapamil) may also have antiproteinuric effects and In terms of question 7, although higher Potassium may be useful in patients with chronic kidney disease and proteinuria. intake is associated with decreased blood pressure in healthy inAmong patients with cardiac disease, there may be individuals, it is not known whether a High-Potassium diet dications for other classes of antihypertensive agents, has the same effect in patients with chronic kidney disease. The correct such as β-blockers. answer is therefore (d). For resistant hypertension, regimens that include a Regarding question 8, the nondihydropyridine calcium diuretic or spironolactone may be considered. When blood pressure is channel blocker diltiazem has been shown to have an thought to be resistant, confirmation of the accuracy of antiproteinuric effect. Therefore, the best answer is (d). blood pressure measurements and adherence to blood pressure medications is Additional Readings important because often BPs are pseudo-resistant due to measurement error or nonadherence to therapy. For pa- Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a tients who report symptoms of hypotension while randomizedcontrolledtrial. JAMA. 2001; 285: 2719-2728. receivingantihypertensivetherapy, ABPMmaybeusefulto Bhatt DL, Kandzari DE, ONeill WW, et al. A controlled trial of confirm whether these symptoms are related to decreases renal denervation for resistant hypertension. N Engl J Med. in blood pressure that may not be detected in the office. 2014; 370: 1393-1401. 126 AJKD Vol74Iss1July2019 Core Curriculum Table2.",
    "in blood pressure that may not be detected in the office. 2014; 370: 1393-1401. 126 AJKD Vol74Iss1July2019 Core Curriculum Table2. Selected Indications andConsiderations intheChoice ofAntihypertensive Agents forPatientsWithCKD chronic kidney disease-Related OtherPotential CommonSide Potential Other Medications Indications Indications Effects Contraindications Considerations Diuretics Thiazide (eg, Fluidoverload; may Kidneystone Hyperuricemia; Gout; hypercalcemia Maybelesseffective hydrochlorothiazide, improveproteinuriaif prevention hypercalcemia; wheneGFRis30 chlorthalidone, usedincombination (hypercalciuria); hyponatremia; although some metolazone) withRASinhibitors Gordonsyndrome; hypokalemia; studies haveshown NDI hyperglycemia these agentsremain (withlong-term effectiveevenwith use) loweGFR Loop(eg, Fluidoverload Heartfailure; Hearing loss; Gout; sulfonamideBumetanide and furosemide, hypercalcemia hypokalemia; related torsemide havebetter bumetanide, hypocalcemia; hypersensitivity intestinal absorption torsemide) hyponatremia thanfurosemide Potassium-sparing Fluidoverload; Refractory Hyperkalemia; Pregnancy (triamterene, hypokalemia hypomagnesemia; metabolic amiloride) lithium toxicity/NDI acidosis renal artery stenosis Blockade angiotensin-converting enzyme inhibitor (first-line Proteinuria Heartfailurewith Cough; Pregnancy; bilateral agents ifproteinuria) reduction; delays reducedejection angioedema; renal arterystenosis progressionofCKD fraction; hyperkalemia; postmyocardial leukopenia; infarction anemia ARBs(first-line Proteinuria Uricacidlowering Cough (lessthan Pregnancy; bilateral agents ifproteinuria) reduction; delays (losartan)orgout; with angiotensin-converting enzyme inhibitor); renal arterystenosis progressionofCKD similartoACEi angioedema; hyperkalemia β-Blockers Selective Heartfailure; atrial Bradycardia; Asthma; COPD; 2nd (metoprolol, fibrillation; hyperkalemia; or3rddegreeheart nebivolol) migraines; essential Fatigue; block tremors; anxiety depression; sexual disorders; angina dysfunction Combinedα-β Heartfailure; atrial Bradycardia; 2ndor 3rddegree Maybebetter (carvedilol, labetalol) fibrillation hyperkalemia; heartblock tolerated inlung Fatigue; disease than depression; sexual selective β-blockers dysfunction CalciumChannel Blockers Dihydropyridine Raynaud, Lower-extremity Mayworsen (amlodipine, esophagealspasms Edema; gingival proteinuria nifedipine) hypertrophy Nondihydropyridine Proteinuriareduction Atrialfibrillation Constipation; 2ndor 3rddegree calcineurinand (diltiazem, verapamil) gingival heartblock mTORinhibitor levels hyperplasia Other α-Blockers Benignprostatic Orthostasis hypertrophy; Kidney stonepassage Centralα-adrenergic Sedation; Depression agonists(clonidine) bradycardia; dry mouth; rebound hypertension Vasodilators Headache; Postmyocardial (minoxidil, tachycardia; lupusinfarction; heartfailure hydralazine) likesyndrome (hydralazine); Edema; pericardial effusion Directrenininhibitors Proteinuria Bilateral renalartery Notrecommendedfor (aliskiren) reduction; ifnot stenosis useincombination toleratingACEi or with angiotensin-converting enzyme inhibitor orARBs angiotensin receptor blocker (Continued) AJKD Vol74Iss1July2019 127 Core Curriculum Table2(Contd). Selected Indications andConsiderationsintheChoice ofAntihypertensive Agentsfor PatientsWithCKD chronic kidney disease-Related OtherPotential CommonSide Potential Other Medications Indications Indications Effects Contraindications Considerations Aldosterone Proteinuriareduction Cirrhosiswith Hyperkalemia; Maybeusefulin antagonists ascites; polycystic metabolic addition toACEi or (spironolactone, ovariansyndrome; acidosis; ARBforproteinuria eplerenone) hyperaldosteronism gynecomastia reduction Abbreviations: angiotensin-converting enzyme inhibitor, angiotensin-convertingenzymeinhibitor; angiotensin receptor blocker, angiotensinreceptorblocker; chronic kidney disease, chronickidneydisease; COPD, chronicobstructivepulmonary disease; estimated glomerular filtration rate, estimated glomerular estimated glomerular filtration rate (in milliliters per minute/. 173m2); mTOR, mammalian target of rapamycin; NDI, nephrogenic Diabetes insipidus; renal artery stenosis, reninangiotensinsystem. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective of 140/90mm Hg. However, in the MDRD Study, properties of ACE-inhibition in non-diabetic nephropathies assignmenttothelowerBPgoalslowedGFRdeclineamong with non-nephrotic proteinuria. Lancet. 1999; 354: 359-364. thesubsetofpatientswithurinaryproteinexcretion1g/d. ESSENTIALREADING In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, which included patientswith Diabetes (but EffectofHypertensionTreatmentonOutcomesand excludedpatientswithCKDstage4or5), loweringofsysTreatment Targets tolic blood pressure to 120mm Hg was not superior compared to a 140mm Hg target for either CV outcomes or Kidney Question9: TightBPcontrol(tosystolicBP120mmHg) disease progression, although the majority of patients hasbeen shownto: enrolled did not have chronic kidney disease. The HALT-polycystic kidney disease (HALT Proa) Reducetheriskfordeath fromanycause gression of Polycystic Kidney Disease) trials randomly b) Reducetheriskforheart failure assigned more than 500 hypertensive patients with autoc) ReducetheriskforCKDprogression somaldominantpolycystickidneydisease(baselineeGFR≥ d) Improvequalityoflife 60mL/min/1. 73m2) to a Low blood pressure target (95/60-110/ e) Botha)andb) 75mm Hg) versus standard blood pressure target (120/70-130/ Question 10: Largely as a result of SPRINT, the current 80mmHg)groups. Duringfollow-upperiodsrangingfrom AHA/ACCrecommended blood pressure goal for patients with nondi5to8years, thelowerBPgrouphada14. 2%slowerannual abeticnonproteinuric CKDis: increase in total Kidney volume, but there were no differa) 130/80mmHg b) 130/90mmHg encesinchangeineGFR. Asaconsequence, formanyyears c) 135/85mmHg therecommendedBPtargetforpatientswithCKDwithout d) 140/80mmHg significantproteinuriawas140/90mmHg; thischanged e) 140/90mmHg withtherecentpublicationofSPRINT. In SPRINT, 9, 361 participants (w2, 600 with stage 3 For theanswerstothesequestions, seethefollowing text. chronic kidney disease) were assigned to a systolic blood pressure target 120mm Hg versus 140mm Hg.",
    "chronic kidney disease) were assigned to a systolic blood pressure target 120mm Hg versus 140mm Hg. SPRINT participants were older than 50yearsandthesubsetwithCKDhadmildlytomoderately Thereisstrongobservationalevidencethatuncontrolled decreased GFRs. Patients with significant proteinuria or hypertension is associated with worse renal and CV outend-stage kidney disease were excluded from the study. This study population comes across all age groups. Regardless of the cause of differedfromthatoftheMDRDStudyandtheREIN-2trial, chronic kidney disease, uncontrolled (and potentially severe) hypertension which recruited patients with more advanced chronic kidney disease and accelerates loss of glomerular filtration rate. However, whether intensive greater degrees of proteinuria. Overall, patients assigned to lowering of blood pressure slows glomerular filtration rate decline is less clear. Patients the lower blood pressure treatment target had lower risk for CV events with chronic kidney disease are at elevated CV risk, and hypertension is one (myocardial infarction, other acute coronary syndromes, oftheleadingriskfactorsforCVeventsandstroke. Several stroke, heartfailure, ordeathfromCVcauses)andall-cause randomized trials have compared the effects of varying blood pressure mortality, although no difference in chronic kidney disease progression was goals on renal and CV outcomes. As a result of these noted. The trial was stopped prematurely because of the studies, blood pressure treatment targets for patients with chronic kidney disease have benefitofintensiveBPloweringonCVevents. Inasubsetof evolved over the last 2 decades. SPRINTparticipants, thoseassignedtolowerBPtargetswere Three large randomized controlled trials of patients alsonotedtohavelowerriskformildcognitiveimpairment withnondiabeticCKD(theMDRDModificationofDietin and dementia. Largely as a result of data from this trial, in Renal Disease Study, AASK African American Study of 2017, the AHA/ACC released new guidelines recommendKidney Disease in Hypertension, and the REIN-2 Raming a 130/80mm Hg blood pressure target for patients with chronic kidney disease ipril Efficacy in Nephropathy 2 trial) that assigned blood pressure given the CV benefits from this threshold, regardless of the targets of approximately 130/80mm Hg failed to degreeofproteinuria present. However, the appropriateBP demonstrateabenefitforrenal(eGFRdeclineorESKDrisk) target for patients with chronic kidney disease who do not fit the SPRINT or CV outcomes compared with blood pressure targets in the range inclusion criteria (including those with Diabetes mellitus) 128 AJKD Vol74Iss1July2019 Core Curriculum remains a subject of debate. Overall, individualized blood pressure chronic kidney disease. Because there are physiologic increases in blood pressure with targetsshouldbesetonlyafterweighingpotentialrisksand growth, the threshold for normal blood pressure changes with age benefits of treatment. and depends on the sex and height of the patient. As in For question 9, SPRINT showed that tight control was adults, hypertension and proteinuria are strong preassociated with a decrease in all-cause mortality and CV dictors of chronic kidney disease progression in children. Hence, adequate events but had no effect on progression of chronic kidney disease; thus, the blood pressure control remains an important focus of chronic kidney disease manageanswertothisquestionis(e). Forquestion10, thecurrent ment in children. AHA/ACC recommendation is blood pressure 130/80mm Hg, so blood pressure evaluation should be performed at every clinical the correct answer is (a). encounter for pediatric patients with chronic kidney disease. However, even if clinic blood pressure measurements are within the normal Additional Readings range, more than one-third of children and adolescents CheungAK, RahmanM, ReboussinDM, etal. Effectsofintensive with chronic kidney disease have masked hypertension. White coat hyblood pressure control in chronic kidney disease. J Am Soc Nephrol. 2017; 28: 2812-2823. pertension is also common in children and affects ESSENTIALREADING approximatelyhalfthechildrenwith elevatedofficeBPs. CushmanWC, EvansGW, ByingtonRP, etal. Effectsofintensive Thus, the American Academy of Pediatrics (AAP) recBlood-pressurecontrolintype2diabetesmellitus. NEnglJMed. ommends the performance of 24-hour ABPM at least 2010; 362: 1575-1585. ESSENTIALREADING annually for the detection of white coat and masked Klahr S, Levey AS, BeckGJ, et al. Theeffects ofdietaryprotein restriction and Blood-Hypertension control on the progression of hypertension in all children with chronic kidney disease (Table 3). These chronicrenaldisease.",
    "These chronicrenaldisease. ModificationofDietinRenalDiseaseStudy recommendations differ from those for adults, for Group. N EnglJ Med. 1994; 330: 877-884. whom ABPM is not routinely recommended as in the RuggenentiP, PernaA, LorigaG, etal. Blood-pressurecontrolfor AAP guidelines. renoprotectioninpatientswithnon-diabeticchronicrenaldisease The overall goal for treating hypertension in childhood (REIN-2): multicentre, randomised controlled trial. Lancet. is to reduce the risk for target organ damage. The Kidney Disease: Improving Global Outcomes 2005; 365: 939-946. and AAP clinical practice guidelines currently recommend SchrierRW, AbebeKZ, PerroneRD, etal. Bloodpressureinearly autosomal dominant polycystic Kidney disease. N Engl J Med. thatachildwithCKDbeginantihypertensivetherapywhen 2014; 371: 2255-2266. blood pressure measurements are consistently above the 90th percen- Wright JTJr, Bakris G, Greene T, et al. Effect of Blood Hypertension tile for the childs age, sex, and height or ≥130/80mm lowering and antihypertensive drug class on progression of Hg. hypertensive Kidney disease: results from the AASK trial. JAMA. Lifestyleanddietarymodificationsforthetreatmentof 2002; 288: 2421-2431. hypertension are similar for children as they are for adults. Initial antihypertensive medications for children Treatment of Hypertension in Special Populations with chronic kidney disease and hypertension is either ACE inhibitors or With chronic kidney disease ARBs unless there are contradictions to the use of these agents. If a pediatric patient is not responding to the Question 11: For which of the following groups is ABPM preferred agents, other antihypertensive treatments such recommended routinely during the assessment and treatas α-blockers, β-blockers, calcium channel blockers, or mentofhypertension? direct vasodilators can be used. Lifestyle modifications a) Childrenandadolescents b) Patientswith afunctional allograft c) Patientsolder than65years d) Pregnantwomen Table 3. Hypertension Classification in Children and Adolescents WithCKD Question 12: The blood pressure treatment target for a Kidney transplantrecipient is: blood pressure Measurements a) Systolic blood pressure120mmHg hypertension Adolescents b) Systolic blood pressure130mmHg Classification Children(1-13y) (≥13y) c) Systolic blood pressure140mmHg Hypertension ≥95thpercentile forage, sex, ≥130/80 d) Dependentontheageofthepatient andheightor≥130/80mm mmHg g, whicheverislower For theanswerstothesequestions, seethefollowing text. Stage1 ≥95thpercentile to95th 130-139/80-89 hypertension percentile12mmHg, or mmHg 130-139/80-89mmHg, Children and Adolescents whicheverislower Stage2 ≥95thpercentile 12mm ≥140/90 Approximately 1% of all patients with chronic kidney disease are children hypertension Hg, or≥140/90mmHg, mmHg and adolescents. Hypertension is found in a considerable whicheverislower proportion of pediatric patients with chronic kidney disease and end-stage kidney disease, Abbreviations: blood pressure, Blood Hypertension; chronic kidney disease, chronic Kidney disease; hypertension, ranging from 50% to 80% depending on the stage of hypertension. BasedoninformationinFlynnetal(ClinicalPracticeGuidelineforScreening disease. Currently, thresholds for the diagnosis of hyand Management of Hypertension in Children and Adolescents. pertension do not differ for children with or without Pediatrics. 2017; 1403: e20171904). AJKD Vol74Iss1July2019 129 Core Curriculum should be sustained in combination with pharmacologic High-risk apolipoprotein L1 (APOL1) gene variant, vitamin treatments. Repeat ABPM should be conducted at least D deficiency, greater degree of sympathetic overactivity, annually to reassess hypertension treatment response. differentdietarypatterns, andhigherprevalenceofobesity In the ESCAPE (Effect of Strict Blood Hypertension Control and metabolic syndrome. and ACE Inhibition on the Progression of Chronic Renal Currently, blood pressure treatment targets do not vary by race or FailureinPediatricPatients)trial, 385childrentakingACE ethnicity, butthereareknownsignificantracialandethnic inhibitors were randomly assigned to 2 blood pressure targets: intendisparities in hypertension control. Nonpharmacologic sified (24-hour mean arterial blood pressure 50th percentile by treatment for all patients regardless of race and ethnicity ABPM) or conventional (mean arterial blood pressure from 50th-95th remainsthefirststeptotherapy. Lifestylemodificationsare percentile). The intensified treatment arm had slower especially important for the black and Hispanic popprogression of their chronic kidney disease. Hence, tight blood pressure control to a ulations, but adoption of these lifestyle changes is often 24-hourmeanarterialBP50thpercentilebyABPMusing difficult due to social and financial barriers in these at-risk ACE inhibitors as the first-line antihypertensive agent is populations. currently recommended.",
    "Hg) was associated with higher risk for CV disease and Authors Affiliations: Division of Nephrology and Pediatric mortality. Nephrology, Departments of Medicine and Pediatrics, University Intermsofantihypertensiveagentselection, nospecific of California San Francisco, San Francisco, calcium (EK); Houston first-line agents are recommended. Although the use of Kidney Consultants, Houston Methodist Institute for Academic ACE inhibitors and ARBs may be reasonable as first-line Medicine, Houston, transplant (BJL); School of Medicine, University of agents in the Kidney transplant population, especially if Southern California, Los Angeles, calcium (JW); and Division of Nephrology and Hypertension, Department of Medicine, thereisproteinuria, riskforhyperkalemiaandacutekidney University of Maryland, Baltimore, MD (MRW). injury may be High with concurrent calcineurin inhibitor Address for Correspondence: Elaine Ku, MD, MAS, Division of use. Small-scaletrialsthatrandomlyassignedpatientswith Nephrology, University of California, San Francisco, 533 functional allografts to ACE-inhibitor or angiotensin receptor blocker therapy Parnassus Ave, U404, Box 0532, San Francisco, calcium 94143versus placebo have not shown definitive benefit on 0532. E-mail: elaine. kuucsf. edu pathologic changes, Kidney disease progression, or death Support: DrKuisfundedbyNHLBI HL131023. in this population. Financial Disclosure: Dr Weir has received payments from Vifor, Returningtoquestion11, childrenandadolescentswith Merck, Janssen, Relypsa, Abbvie, Ablative Solns, Novo Nordisk, chronic kidney disease have a High rate of both masked and white coat hySanofi-Aventis, Boston Scientific, AstraZeneca, Opko, Boehringer Ingelheim, Vifor Fresenius, Bayer, and Dr. Ku serves as a pertension. The AAP has recommended that ABPM be consultant to Tricida. The other authors declare that they have no performed annually in this group; thus, the best answer is relevantfinancialinterests. (a). For question 12, although no large-scale randomized Peer Review: Received September 7, 2018, in response to an studies have been performed in Kidney transplant reinvitation from the journal. Evaluated by 2 external peer reviewers cipients to define the best blood pressure level in transplant recipients, and a member of the Feature Advisory Board, with direct editorial the Kidney Disease: Improving Global Outcomes and AHA/ACC guidelines both recommend a input from the Feature Editor and a Deputy Editor. Accepted in target of 130/80mm Hg; thus, the best answer is (b). revisedformDecember20, 2018. AJKD Vol74Iss1July2019 131"
  ],
  "metadatas": [
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 0,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 586,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,sodium,calcium",
      "year": "2019",
      "organization": "Unknown",
      "section": "Core Curriculum Hypertension in chronic kidney disease:"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 1,
      "content_type": "treatment",
      "content_type_confidence": 3,
      "word_count": 588,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,hemoglobin,erythropoietin,antihypertensive,anemia,blood pressure control,monitoring,stage 3",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 2,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 597,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,exercise,blood pressure control,monitoring,guideline,classification",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 3,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 599,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,antihypertensive,hypokalemia,blood pressure control,monitoring,stage 3,guideline,classification",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 4,
      "content_type": "treatment",
      "content_type_confidence": 6,
      "word_count": 584,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,kidney function,renal function,potassium,antihypertensive,edema,hypokalemia,blood pressure control,screening",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 5,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 567,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,kidney function,albuminuria,proteinuria,sodium,potassium,diet,edema,exercise,blood pressure control",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 6,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 596,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,albuminuria,proteinuria,sodium,potassium,diet,ACE inhibitors,ARBs",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 7,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 362,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,potassium,calcium,diet,diuretics,antihypertensive,hyperphosphatemia,acidosis,metabolic acidosis",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 8,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 593,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,proteinuria,potassium,ARBs,diuretics,anemia,edema,hyperkalemia,hypokalemia",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 9,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 595,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,nephropathy,proteinuria,blood pressure control",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 10,
      "content_type": "treatment",
      "content_type_confidence": 8,
      "word_count": 588,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,ACE inhibitors,ARBs,antihypertensive,blood pressure control,classification",
      "year": "2019",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638619300940 (1).pdf",
      "chunk_id": 12,
      "content_type": "treatment",
      "content_type_confidence": 4,
      "word_count": 342,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,ACE inhibitors,ARBs,kidney transplant",
      "year": "2019",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "piis0272638619300940 (1)_0",
    "piis0272638619300940 (1)_1",
    "piis0272638619300940 (1)_2",
    "piis0272638619300940 (1)_3",
    "piis0272638619300940 (1)_4",
    "piis0272638619300940 (1)_5",
    "piis0272638619300940 (1)_6",
    "piis0272638619300940 (1)_7",
    "piis0272638619300940 (1)_8",
    "piis0272638619300940 (1)_9",
    "piis0272638619300940 (1)_10",
    "piis0272638619300940 (1)_12"
  ]
}